Immune Responses After Third Dose of COVID-19-mRNA Vaccination in Patients with Lung Transplatation

Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³, Porntep Siriwanarangsun¹

1. Faculty of Medicine, Western University, Pathumtani Province, Thailand

2. 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

3. Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
 

Corresponding Author: Attapon Cheepsattayakorn, Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100

Copy Right: © 2022 Attapon Cheepsattayakorn, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received Date: August 29, 2022

Published Date: September 05, 2022

Organ transplant recipients had been shortage of target tools or vaccines for infection prevention before COVID-19-vaccine global release [1], whereas a recent study demonstrated that around 76 % of adult-lung-transplant recipients received induction immunosuppression [2]. A recent study on humoral immune response to third dose of COVID-19-mRNA vaccine (mRNA-1273 (Moderna) or BMT162b2 (Pfizer) vaccine) among 114 study participants of lung transplantation with first, second doses of COVID-19-mRNA vaccination immunosuppression medication [3]. The study results demonstrated that after a median of 175 days after the second dose, 22 of 24 lung-transplant recipients (LTR) with third dose vaccination revealed seroconversion (5 of 7 primary non-responders and 17 of 17 primary responders), whereas 94 % and 100 % of seroconversion in healthy controls (HCs) were detected in the first and second doses of COVID-19-mRNA vaccines, compared to only 19 % and 56 % in LTRs, respectively [3]. In consideration of T cell response against SARS-CoV-2-spike S1 and/or S2, 50 % of response was revealed among LTRs, whereas 100 % response was demonstrated among HCs.

In conclusion, a third dose of COVID-19-mRNA vaccination could be benefit in LTRs, whereas decreased humoral and cellular immune responses after two doses of COVID-19-mRNA vaccination were revealed in LTRs.

Reference

1. Altneu E, Mishkin A. COVID-19 vaccination in lung transplant recipients. Indian Journal of Cardiovascular Surgery 2022; 38 (Suppl 2) : S347-S353. DOI: https://doi.org/10.1007/s12055-022-01364-9

2. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant 2018; 37: 1169-1183.

3. Tobudic S, Benazzo A, Koblischke M, Schneider L, Blu?ml S, Winkler F, et al. immune response after mRNA COVID-19 vaccination in lung transplant recipients: a 6-month follow-up. Vaccines 2022; 10: 1130. DOI: https://doi.org/10.3390/vaccines10071130